ValuEngine upgraded shares of Cerecor (NASDAQ:CERC) from a hold rating to a buy rating in a research note released on Thursday morning.
NASDAQ CERC traded down $0.07 during trading on Thursday, reaching $4.41. 29,900 shares of the company’s stock were exchanged, compared to its average volume of 173,212. The company has a market cap of $153.77 million, a PE ratio of 10.45 and a beta of 1.32. The company has a quick ratio of 0.54, a current ratio of 0.62 and a debt-to-equity ratio of 0.75. Cerecor has a fifty-two week low of $1.00 and a fifty-two week high of $5.74.
Cerecor (NASDAQ:CERC) last announced its quarterly earnings results on Thursday, August 9th. The company reported ($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.10). The firm had revenue of $4.79 million for the quarter, compared to the consensus estimate of $4.50 million. Cerecor had a return on equity of 43.87% and a net margin of 15.71%. As a group, research analysts anticipate that Cerecor will post -0.55 EPS for the current fiscal year.
In other news, Director Armistice Capital, Llc bought 6,473 shares of the firm’s stock in a transaction dated Thursday, September 27th. The shares were bought at an average price of $4.71 per share, with a total value of $30,487.83. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Armistice Capital Master Fund bought 1,000,000 shares of the firm’s stock in a transaction dated Friday, August 17th. The stock was purchased at an average cost of $3.91 per share, for a total transaction of $3,910,000.00. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 1,524,535 shares of company stock worth $6,064,552. Company insiders own 80.20% of the company’s stock.
Several institutional investors have recently bought and sold shares of CERC. BlackRock Inc. grew its position in shares of Cerecor by 630.4% in the second quarter. BlackRock Inc. now owns 27,520 shares of the company’s stock valued at $120,000 after purchasing an additional 23,752 shares during the last quarter. Northern Trust Corp grew its position in shares of Cerecor by 182.0% in the first quarter. Northern Trust Corp now owns 31,506 shares of the company’s stock valued at $135,000 after purchasing an additional 20,333 shares during the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in shares of Cerecor in the third quarter valued at approximately $169,000. Finally, Spark Investment Management LLC acquired a new position in shares of Cerecor in the second quarter valued at approximately $288,000. 41.59% of the stock is currently owned by institutional investors.
Cerecor Company Profile
Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Veripred, and Ulesfia for the treatment of inflammation of the skin, joints, lungs, and other organs, as well as asthma, allergies, arthritis, and head lice infestation.
Featured Article: Bond
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.